The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Workshop of the Carolinas 2024 | Considering the key benefits of each JAK inhibitor approved for the treatment of MPNs
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of the four FDA-approved JAK inhibitors for the treatment of myeloproliferative neoplasms (MPNs). Ruxolitinib remains the drug of choice in the front-line setting thanks to its superior performance in trials, with studies demonstrating that early intervention with this drug could prevent disease progression. Dr Bose also underscores the unique benefit of fedratinib and pacritinib in sparing JAK1 inhibition, which may be particularly beneficial for patients suffering from infections. Additionally, momelotinib offers a particular advantage for the management of anemia. Dr Bose emphasizes the importance of selecting JAK inhibitor therapy based on each patient’s specific needs. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support: Incyte, BMS, CTI (Sobi), Morphosys, Karyopharm, Sumitomo, Ajax, Disc, Ionis, Geron, Janssen, Cogent, Blueprint, Kartos, Telios.; Honoraria/consulting fees: Incyte, BMS, CTI (Sobi), GSK, Abbvie, Morphosys, Pharma Essentia, Sumitomo, Karyopharm, Ionis, Disc, Geron, Morphic, Jubilant, Ono, Novartis, Blueprint, Cogent.
